Investors’ outlook regarding the stock price performance over the year has been a mixed bag, with a range of optimism to pessimism depending on their perspective. The index has shown a price gain of 319.89% this year. Over the last six months, there has been a weaker performance of 295.19%. The price of CRVS leaped by -9.77% during the last 30 days period. For the last 5-days stocks have slided -7.86%.
Corvus Pharmaceuticals Inc experienced a rather steady stock market performance. The highest value in the past year was recorded at $10.00 on 11/13/24 and the lowest value was $1.30 on 04/18/24.
52-week price history of CRVS Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Corvus Pharmaceuticals Inc’s current trading price is -26.10% away from its 52-week high, while its distance from the 52-week low is 468.46%. The stock’s price range during this period has varied between$1.30 and $10.00. The Corvus Pharmaceuticals Inc’s shares, which operate in the Healthcare, saw a trading volume of around 1.22 million for the day, a figure considerably higher than their average daily volume of 0.79 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Corvus Pharmaceuticals Inc (CRVS) has experienced a quarterly rise of 34.85% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 474.87M and boasts a workforce of 28 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 6.23, with a change in price of +4.81. Similarly, Corvus Pharmaceuticals Inc recorded 687,042 in trading volume during the last 100 days, posting a change of +186.43%.
CRVS’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for CRVS stands at 0.03. Similarly, the long-term debt-to-equity ratio is also 0.00.
CRVS Stock Stochastic Average
Corvus Pharmaceuticals Inc’s raw stochastic average for the past 50 days is presently 42.00%, as of today. This marks a increase from the raw stochastic average of the last 20 days, which was 30.55%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 11.76% and 10.31%, respectively.
